Neofect is showing strong performance. This is interpreted as being influenced by the news that South Korea will lead the development of international standards related to 'brain-computer interface' technology.
As of 9:29 AM on the 11th, Neofect is trading at 1,669 KRW, up 10.94% from the previous day.
The National Institute of Technology and Standards under the Ministry of Trade, Industry and Energy announced on the same day that the new international standard proposal (NP) for the 'Brain-Computer Interface (BCI) Data Format' proposed by South Korea was finally approved at the recent BCI International Standardization Committee General Assembly.
BCI, which is being developed mainly by advanced countries such as the United States, is being utilized in various industries including medical, health, and mobility to assist people with physical movement difficulties or to control cars using only thoughts.
Earlier, Elon Musk, CEO of Tesla, also founded a biotech startup called 'Neuralink.' Neuralink's business goal is to implant a chip called 'Neural Lace' into the human brain and link the human brain nerves (neuro) with computer chips.
Recently, 'Synchron,' known as a rival to Neuralink, has completed preparations for clinical trials in the United States. The company recently completed the registration of six patients to conduct a clinical trial for the COMMAND maintenance therapy study on its brain-computer interface (BCI) device called the 'Synchron Switch.'
Meanwhile, Neofect's affiliate, Wibrain, is known to have secured a project for a BCI device for personal mobility at Hyundai Motor Company's Robotics Lab and is participating in its development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
